 Pyridines
"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1983 | 2 | 0 | 2 | | 1985 | 2 | 0 | 2 | | 1987 | 2 | 0 | 2 | | 1988 | 1 | 0 | 1 | | 1989 | 2 | 0 | 2 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 1 | 2 | 3 | | 1995 | 1 | 2 | 3 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 2 | 3 | | 1999 | 1 | 1 | 2 | | 2000 | 4 | 1 | 5 | | 2001 | 2 | 5 | 7 | | 2002 | 2 | 0 | 2 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 4 | 5 | | 2005 | 1 | 6 | 7 | | 2006 | 4 | 1 | 5 | | 2007 | 4 | 5 | 9 | | 2008 | 5 | 3 | 8 | | 2009 | 8 | 5 | 13 | | 2010 | 14 | 5 | 19 | | 2011 | 11 | 2 | 13 | | 2012 | 6 | 5 | 11 | | 2013 | 5 | 4 | 9 | | 2014 | 6 | 2 | 8 | | 2015 | 7 | 2 | 9 | | 2016 | 8 | 5 | 13 | | 2017 | 4 | 4 | 8 | | 2018 | 6 | 6 | 12 | | 2019 | 1 | 3 | 4 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
-
George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019 11; 24(11):1497-1501.
-
Strohbehn GW, Vokes EE. Palbociclib: a new partner for cetuximab? Lancet Oncol. 2019 09; 20(9):1195-1196.
-
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.
-
Al-Majid AM, Islam MS, Atef S, El-Senduny FF, Badria FA, Elshaier YAMM, Ali M, Barakat A, Motiur Rahman AFM. Synthesis of Pyridine-Dicarboxamide-Cyclohexanone Derivatives: Anticancer and a-Glucosidase Inhibitory Activities and In Silico Study. Molecules. 2019 Apr 04; 24(7).
-
Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 04; 20(4):581-590.
-
Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2019 04 01; 25(7):2305-2313.
-
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7.
-
Paratala BS, Chung JH, Williams CB, Yilmazel B, Petrosky W, Williams K, Schrock AB, Gay LM, Lee E, Dolfi SC, Pham K, Lin S, Yao M, Kulkarni A, DiClemente F, Liu C, Rodriguez-Rodriguez L, Ganesan S, Ross JS, Ali SM, Leyland-Jones B, Hirshfield KM. RET rearrangements are actionable alterations in breast cancer. Nat Commun. 2018 11 16; 9(1):4821.
-
Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|